Summary Tumour markers now have an established role in tumour diagnosis and patient management. However, antibodies used to detect these tumour markers have in some instances proved unreliable, with a low rate of sensitivity and specificity. In this study we wished to evaluate the role of a commercial antibody to myoglobin as a marker of rhabdomyosarcomas. The purpose of this investigation was to assess the sensitivity and specificity of myoglobin antiserum as a marker of rhabdomyosarcomas. This was performed by reacting a large number of tumours (sarcomas, carcinomas and melanomas) with a polyclonal anti human myoglobin antiserum. Staining was demonstrated in 60% of rhabdomyosarcomas. Only two tumours from a total of 226 non-skeletal muscle tumours showed a positive reaction (0.88%). One was a leiomyosarcoma and the other had been classified as an undifferentiated sarcoma but a rhabdomyosarcoma was included in its differential diagnosis. It is of interest that both had been earlier irradiated. This antiserum was therefore a specific but not a very sensitive tumour marker. Its rate of staining of rhabdomyosarcomas is compared with the results in the literature. A great disparity is found and the reasons for this are discussed.
A tumour marker is a tumour derived or associated product the detection of which indicates the presence of a specific line of differentiation in a tumour. Any antigenic determinant specific to a cell type may be used as a tumour marker. These may include hormones, enzymes, intermediate filaments, proteins, etc. Their presence is identified by the use of antibodies raised against an antigenic determinant in or on the tumour cell.
Tumour markers now have an established role in clinical practice as aids in the detection of primary or recurrent tumour, in tumour treatment (by targetting the antibody with a cytotoxic drug) and in screening for certain malignancies. Since the advent of immunocytochemical techniques which permit the detection of tumour markers in formalin fixed material, the histopathologist has discovered that many of these markers are valuable additional diagnostic tools.
However, it is essential that the antibodies used to detect them are specific and sensitive for the tumour in question. It is therefore essential that these antibodies are rigorously tested on a large group of tumours under controlled conditions such as in this study.
Rhabdomyosarcomas account for 19% of the sarcomas seen in a pathology department (Russel et al., 1977) . The morphological appearances of these tumours can be variable and their histopathological diagnosis is sometimes difficult, especially in the absence of cross striations. Diagnosis is then based either on immunocytochemical staining for a specific tumour marker or on electron microscopy. As the latter is expensive and time-consuming and requires the availability of an electron microscope, these tumours are generally first subjected to immunocytochemical analysis. The expression of myoglobin by these sarcomas is therefore regarded as a useful diagnostic marker (Corson & Pinkus, 1981; Kindblom et al., 1982; Brooks, 1982 (Leader et al., 1986a (Leader et al., ,b,c, 1987a . They represent some of the sarcomas seen over a 20-year period in this institution. Only tumours with available blocks were used in this study. All had been formalin fixed and paraffin embedded. All sarcomas had been diagnosed by MacKenzie (1970) , an acknowledged authority in soft tissue tumour diagnosis. His criteria for the diagnosis of sarcomas, including rhabdomyosarcomas, were similar to those of Enzinger & Weiss (1983) . The subtypes of rhabdomyosarcomas included in the study are shown in Table II 
Results
The results are summarised in Table I and those of the rhabdomyosarcomas are shown in more detail in Table II . Tumour cells in 15 of the 25 rhabdomyosarcomas stained ( Figure 1 ) and two results were equivocal. All the main subtypes of rhabdomyosarcomas were represented amongst the positive cases (5/7 alveolar, 7/11 embryonal, 3/5 pleomorphic). Staining in all cases was granular and restricted to the cytoplasm; membrane staining was not particularly intense. Cross striations were highlighted by the staining. The number of positively staining cells in each tumour Br. J. Cancer (1989), 59, 106-109 Table II ). There were only two positive reactions amongst the 183 nonrhabdomyosarcomatous sarcomas, a leiomyosarcoma and an undifferentiated sarcoma (Figures 2 and 3) (Eusebi et al., 1984) . It is suggested by the authors that myoglobin may be transferred from skeletal muscle to the infiltrating tumour cells.
The results of this study using antiserum from Dakopatts show that only 60% of rhabdomyosarcomas stained (Table  l) . So as to exclude the possibility of incorrect diagnosis, the original histopathological diagnosis of the rhabdomyosarcomas in this study was reviewed. In each the diagnosis was confirmed. All negatively staining rhabdomyosarcomas were restained using similar trypsinisation to the initial study and a similar dilution of primary antisera. No additional staining was seen. Seven papers have examined the staining reactions of anti human myoglobin antisera with rhabdomyosarcomas (Table III) (Corson & Pinkus, 1981; Brooks, 1982; Kindblom et al., 1982; Tsokos et al., 1983; Kahn et al., 1983; Kagawa et al., 1983; de Jong et al., 1984) . The results in three of the seven suggest that myoglobin is a useful marker of skeletal muscle differentiation (Corson & Pinkus, 1981; Brooks, 1982; Kindblom et al., 1982) . However, three papers report positive staining only in 47, 36 and 50% of rhabdomyosarcomas (de Jong et al., 1983; Kahn et Kagawa et al., 1983) respectively. In another study it was found to be a useful marker of alveolar but not of embryonal rhabdomyosarcomas; no pleomorphic rhabdomyosarcomas were included in the study (Tsokos et al., 1983) .
This review of the literature showing reported rates of positive staining ranging from 100 to 36% in different series (Table III) therapy may give misleading results with immunocytochemical tumour markers (Leader et al., 1986b (Leader et al., , 1987a . The reason for this is unclear; it may be that the cells 'mop up' the primary antibody non-specifically. This is suggested by positivity in irradiated viable skeletal muscle using anti factor VIII related antigen in an earlier study (Leader, 1986b) . It may also be related in some instances to the induction of a new line of differentiation by radiotherapy. The undifferentiated tumour can almost certainly be reclassified as a rhabdomyosarcoma in view of its positivity for myoglobin and desmin and therefore it can be regarded as a genuine positive reaction. Therefore in this study there was only one positive tumour among 225 non-rhabdomyosarcomatous tumours.
A number of studies have also investigated the value of other markers such as myosin (Tsokos et al., 1983) , creatinine kinase (Tsokos et al., 1983) , creatinine kinase MM (Tsokos et al., 1983; Kahn et al., 1983) , calsequestrin and calcium magnesium-dependent ATPase of sarcoplasmic reticulum (Kahn et al., 1983) and desmin (Kahn et al., 1983; Leader et al., 1987a; Kias et al., 1987) in the diagnosis of rhabdomyosarcomas. The first three of these appear to be more sensitive indicators of skeletal muscle differentiation than myoglobin; however, they are associated with a significant false positive reaction rate among carcinomas (approximating 30%) and therefore their discriminatory value is limited. Desmin, ATPase and calsequestrin were found in a higher percentage of rhabdomyosarcomas than myoglobin, but the specificity of only desmin has been investigated and this in only one study (Leader et al., 1987a) .
Tumour markers have a useful role in diagnostic surgical pathology. Positive staining must be carefully interpreted and a positive result accepted only when the tumour cells are viable, not adjacent to foci of tumour necrosis and when the staining is discrete, granular and confined to or within the cell. When one uses these criteria for a positive reaction and when one uses appropriate positive and negative controls, positivity in a cell reflects the presence within the cell of an epitope to which the antibody has been raised. This result therefore can be used to indicate that the tumour cell shows a specific line of differentiation when the epitope being recognised is specific. Of course it must be borne in mind that, with polyclonal antisera in particular, cross reactivity may be found with other types of tumours due to the variety of possible epitopes recognised by this type of antiserum. 
